Gilead acquires XinThera to strengthen pipeline in oncology and inflammation
Betsy Goodfellow | May 10, 2023 | News story | Sales and Marketing | Gilead, Oncology, XinThera, inflammation, oncology
Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, US. This acquisition aims to strengthen Gilead’s clinical development pipeline through the addition of XinThera’s oncology and inflammation assets.
Gilead will gain the rights to a portfolio of small molecule inhibitors that target PARP1 for oncology and MK2 for inflammatory diseases; these could enter clinical trials by the end of 2023. Both the oncology and inflammation programmes have the potential to address various indications, with a wide range of development opportunities both alone and in combination with Gilead’s portfolio.
Financial terms of the agreement have not been disclosed.
Flavius Martin, MD, executive vice president of research at Gilead Sciences, commented: “The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases. Guided by our scientific framework, this acquisition will allow us to further expand our early pipeline of diverse assets that will continue to fuel our durable late-phase portfolio.”
Chris LeMasters, who worked as XinThera’s chief executive officer, added: “Gilead and XinThera share similar missions to discover new therapies to treat cancer and inflammatory diseases, which drive our determination to unlock the body’s ability to better respond to these diseases. We are eager to join Gilead and together explore the potential of our precision medicines as critical components of the next generation of therapies targeting diseases with high unmet need.”
Betsy Goodfellow
Related Content
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery
Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration …
Genentech shares positive results from phase 3 trial for breast cancer treatment
Genentech, a member of the Roche Group, has announced positive results from the phase 3 …
